[
  {
    "sourceRefId": "ref-003",
    "filename": "Jing _lu _et_al.pdf",
    "metricName": "burden",
    "yearOrRange": "2017",
    "value": 444,
    "unit": "cases",
    "population": null,
    "notes": "t  al.  Global  cancer  in  women:  burden  and\ntrends.Cancer Epidemiol Biomarkers Prev. 2017;26(4):444–457.\n2.   Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017.CA Cancer J Clin. 2017;\n67(1):7",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2006",
    "value": 99,
    "unit": "%",
    "population": null,
    "notes": "This  provides  a  power  of  99%  \nto detect a 5-year cumulative incidence rate of 9% in 2006–\n2007  compared  with  10%  cumulative  incidence  in  2001–\n2002\n2\n  assuming  a  Poisson  distribution ",
    "pageHint": 6,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2006",
    "value": 9,
    "unit": "%",
    "population": null,
    "notes": "This  provides  a  power  of  99%  \nto detect a 5-year cumulative incidence rate of 9% in 2006–\n2007  compared  with  10%  cumulative  incidence  in  2001–\n2002\n2\n  assuming  a  Poisson  distribution ",
    "pageHint": 6,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2006",
    "value": 10,
    "unit": "%",
    "population": null,
    "notes": "This  provides  a  power  of  99%  \nto detect a 5-year cumulative incidence rate of 9% in 2006–\n2007  compared  with  10%  cumulative  incidence  in  2001–\n2002\n2\n  assuming  a  Poisson  distribution ",
    "pageHint": 6,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2006",
    "value": 5,
    "unit": "%",
    "population": null,
    "notes": "This  provides  a  power  of  99%  \nto detect a 5-year cumulative incidence rate of 9% in 2006–\n2007  compared  with  10%  cumulative  incidence  in  2001–\n2002\n2\n  assuming  a  Poisson  distribution ",
    "pageHint": 6,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2006",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "This  provides  a  power  of  99%  \nto detect a 5-year cumulative incidence rate of 9% in 2006–\n2007  compared  with  10%  cumulative  incidence  in  2001–\n2002\n2\n  assuming  a  Poisson  distribution ",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2006",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "This  provides  a  power  of  99%  \nto detect a 5-year cumulative incidence rate of 9% in 2006–\n2007  compared  with  10%  cumulative  incidence  in  2001–\n2002\n2\n  assuming  a  Poisson  distribution ",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2006",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "This  provides  a  power  of  99%  \nto detect a 5-year cumulative incidence rate of 9% in 2006–\n2007  compared  with  10%  cumulative  incidence  in  2001–\n2002\n2\n  assuming  a  Poisson  distribution ",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2006",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "This  provides  a  power  of  99%  \nto detect a 5-year cumulative incidence rate of 9% in 2006–\n2007  compared  with  10%  cumulative  incidence  in  2001–\n2002\n2\n  assuming  a  Poisson  distribution ",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2006",
    "value": 99,
    "unit": "year",
    "population": null,
    "notes": "This  provides  a  power  of  99%  \nto detect a 5-year cumulative incidence rate of 9% in 2006–\n2007  compared  with  10%  cumulative  incidence  in  2001–\n2002\n2\n  assuming  a  Poisson  distribution ",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2006",
    "value": 2006,
    "unit": "year",
    "population": null,
    "notes": "This  provides  a  power  of  99%  \nto detect a 5-year cumulative incidence rate of 9% in 2006–\n2007  compared  with  10%  cumulative  incidence  in  2001–\n2002\n2\n  assuming  a  Poisson  distribution ",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2006",
    "value": 2007,
    "unit": "year",
    "population": null,
    "notes": "This  provides  a  power  of  99%  \nto detect a 5-year cumulative incidence rate of 9% in 2006–\n2007  compared  with  10%  cumulative  incidence  in  2001–\n2002\n2\n  assuming  a  Poisson  distribution ",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2006",
    "value": 10,
    "unit": "year",
    "population": null,
    "notes": "This  provides  a  power  of  99%  \nto detect a 5-year cumulative incidence rate of 9% in 2006–\n2007  compared  with  10%  cumulative  incidence  in  2001–\n2002\n2\n  assuming  a  Poisson  distribution ",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2006",
    "value": 2001,
    "unit": "year",
    "population": null,
    "notes": "This  provides  a  power  of  99%  \nto detect a 5-year cumulative incidence rate of 9% in 2006–\n2007  compared  with  10%  cumulative  incidence  in  2001–\n2002\n2\n  assuming  a  Poisson  distribution ",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2006",
    "value": 2002,
    "unit": "year",
    "population": null,
    "notes": "This  provides  a  power  of  99%  \nto detect a 5-year cumulative incidence rate of 9% in 2006–\n2007  compared  with  10%  cumulative  incidence  in  2001–\n2002\n2\n  assuming  a  Poisson  distribution ",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 93,
    "unit": "%",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 86,
    "unit": "%",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 96,
    "unit": "%",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 83,
    "unit": "%",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 99,
    "unit": "%",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 4.5,
    "unit": "year",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 167,
    "unit": "year",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 93,
    "unit": "year",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 95,
    "unit": "year",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 86,
    "unit": "year",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 96,
    "unit": "year",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 95,
    "unit": "year",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 95,
    "unit": "year",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 83,
    "unit": "year",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 99,
    "unit": "year",
    "population": null,
    "notes": "However,  an  Australian  validation  \nstudy  of  167  BC  cases  has  reported  endocrine  treatment  is  \na very good proxy for oestrogen receptor status with a sensi-\ntivity  of  93%  (95%  CI:  86",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 46.7,
    "unit": "%",
    "population": null,
    "notes": "We found from 2018 to\n2040 the APC in incidence of metastatic cancer in the US will\ndecrease by 0.70 per 100,000 individuals, and long-term survi-\nvorship will increase by 46.7%",
    "pageHint": 1,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2019",
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "The ARIMA APC model\nwas used to predict incidence with a 95% confidence interval of\nindividual metastatic diseases, and metastatic disease to specific\nsites, among ages 0 to 85 from 2019 to 2040",
    "pageHint": 1,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 0.8,
    "unit": "per 100,000",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 0.7,
    "unit": "per 100,000",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 0.7,
    "unit": "per 100,000",
    "population": null,
    "notes": "We found from 2018 to\n2040 the APC in incidence of metastatic cancer in the US will\ndecrease by 0.70 per 100,000 individuals, and long-term survi-\nvorship will increase by 46.7%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 0,
    "unit": "count",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 0,
    "unit": "count",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 0,
    "unit": "count",
    "population": null,
    "notes": "We found from 2018 to\n2040 the APC in incidence of metastatic cancer in the US will\ndecrease by 0.70 per 100,000 individuals, and long-term survi-\nvorship will increase by 46.7%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2000",
    "value": 0,
    "unit": "count",
    "population": null,
    "notes": "All incidence rates were age-adjusted to the 2000 US\nstandard  population  and  reported  per  100,000  individuals",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "burden",
    "yearOrRange": "2040",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "We assess the burden of metastatic\ncancer to 2040 by (1) characterizing past, current, and forecasted incidence trends, and (2)\nestimating odds of long-term (5-year) survivorship",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Average annual\npercentage change (AAPC) was calculated to describe cancer incidence trends from 1988 to\n2018",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Average annual\npercentage change (AAPC) was calculated to describe cancer incidence trends from 1988 to\n2018",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "The objectives of this work are to (1) report the\nepidemiology of metastatic cancer in the US with respect to past,\ncurrent, and forecasted trends in incidence and (2) estimate odds\nof long-term survi",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "We found from 2018 to\n2040 the APC in incidence of metastatic cancer in the US will\ndecrease by 0.70 per 100,000 individuals, and long-term survi-\nvorship will increase by 46.7%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "We found from 2018 to\n2040 the APC in incidence of metastatic cancer in the US will\ndecrease by 0.70 per 100,000 individuals, and long-term survi-\nvorship will increase by 46.7%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2000",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "All incidence rates were age-adjusted to the 2000 US\nstandard  population  and  reported  per  100,000  individuals",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2019",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "The ARIMA APC model\nwas used to predict incidence with a 95% confidence interval of\nindividual metastatic diseases, and metastatic disease to specific\nsites, among ages 0 to 85 from 2019 to 2040",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2019",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "The ARIMA APC model\nwas used to predict incidence with a 95% confidence interval of\nindividual metastatic diseases, and metastatic disease to specific\nsites, among ages 0 to 85 from 2019 to 2040",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "For each\ncancer type, incidence by age from 0–84 and single calendar year\n(from 1988 to 2018) were directly obtained from SEER",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "For each\ncancer type, incidence by age from 0–84 and single calendar year\n(from 1988 to 2018) were directly obtained from SEER",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Joinpoint regression models\nwere employed to analyze long-term trends in metastatic cancer\nincidence from the original SEER data and the ARIMA predic-\ntions (1988–2040)",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Joinpoint regression models\nwere employed to analyze long-term trends in metastatic cancer\nincidence from the original SEER data and the ARIMA predic-\ntions (1988–2040)",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 0.8,
    "unit": "per 100,000",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 0.7,
    "unit": "per 100,000",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 0.7,
    "unit": "per 100,000",
    "population": null,
    "notes": "We found from 2018 to\n2040 the APC in incidence of metastatic cancer in the US will\ndecrease by 0.70 per 100,000 individuals, and long-term survi-\nvorship will increase by 46.7%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 46.7,
    "unit": "per 100,000",
    "population": null,
    "notes": "We found from 2018 to\n2040 the APC in incidence of metastatic cancer in the US will\ndecrease by 0.70 per 100,000 individuals, and long-term survi-\nvorship will increase by 46.7%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 11,
    "unit": "cases",
    "population": null,
    "notes": "Zaorsky\n11\n✉\nBackgroundPrevious  studies  have  demonstrated  epidemiological  trends  in  individual\nmetastatic cancer subtypes; however, research forecasting long-term incidence trends and\nprojected",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "burden",
    "yearOrRange": "2040",
    "value": 2040,
    "unit": "year",
    "population": null,
    "notes": "We assess the burden of metastatic\ncancer to 2040 by (1) characterizing past, current, and forecasted incidence trends, and (2)\nestimating odds of long-term (5-year) survivorship",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 1988,
    "unit": "cases",
    "population": null,
    "notes": "Average annual\npercentage change (AAPC) was calculated to describe cancer incidence trends from 1988 to\n2018",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 2018,
    "unit": "cases",
    "population": null,
    "notes": "Average annual\npercentage change (AAPC) was calculated to describe cancer incidence trends from 1988 to\n2018",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 80,
    "unit": "per 100,000",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 100,
    "unit": "per 100,000",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 0,
    "unit": "per 100,000",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 1988,
    "unit": "per 100,000",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 2018,
    "unit": "per 100,000",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 70,
    "unit": "per 100,000",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 100,
    "unit": "per 100,000",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 0,
    "unit": "per 100,000",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 2018,
    "unit": "per 100,000",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 2040,
    "unit": "per 100,000",
    "population": null,
    "notes": "ResultsThe average annual percent change (AAPC) in incidence of metastatic cancer\ndecreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease\nby 0.70 per 100,000 individuals ",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 2040,
    "unit": "cases",
    "population": null,
    "notes": "The objectives of this work are to (1) report the\nepidemiology of metastatic cancer in the US with respect to past,\ncurrent, and forecasted trends in incidence and (2) estimate odds\nof long-term survi",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 2018,
    "unit": "per 100,000",
    "population": null,
    "notes": "We found from 2018 to\n2040 the APC in incidence of metastatic cancer in the US will\ndecrease by 0.70 per 100,000 individuals, and long-term survi-\nvorship will increase by 46.7%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 2040,
    "unit": "per 100,000",
    "population": null,
    "notes": "We found from 2018 to\n2040 the APC in incidence of metastatic cancer in the US will\ndecrease by 0.70 per 100,000 individuals, and long-term survi-\nvorship will increase by 46.7%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 70,
    "unit": "per 100,000",
    "population": null,
    "notes": "We found from 2018 to\n2040 the APC in incidence of metastatic cancer in the US will\ndecrease by 0.70 per 100,000 individuals, and long-term survi-\nvorship will increase by 46.7%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 100,
    "unit": "per 100,000",
    "population": null,
    "notes": "We found from 2018 to\n2040 the APC in incidence of metastatic cancer in the US will\ndecrease by 0.70 per 100,000 individuals, and long-term survi-\nvorship will increase by 46.7%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 0,
    "unit": "per 100,000",
    "population": null,
    "notes": "We found from 2018 to\n2040 the APC in incidence of metastatic cancer in the US will\ndecrease by 0.70 per 100,000 individuals, and long-term survi-\nvorship will increase by 46.7%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 46,
    "unit": "per 100,000",
    "population": null,
    "notes": "We found from 2018 to\n2040 the APC in incidence of metastatic cancer in the US will\ndecrease by 0.70 per 100,000 individuals, and long-term survi-\nvorship will increase by 46.7%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2000",
    "value": 2000,
    "unit": "per  100,000",
    "population": null,
    "notes": "All incidence rates were age-adjusted to the 2000 US\nstandard  population  and  reported  per  100,000  individuals",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2000",
    "value": 100,
    "unit": "per  100,000",
    "population": null,
    "notes": "All incidence rates were age-adjusted to the 2000 US\nstandard  population  and  reported  per  100,000  individuals",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2000",
    "value": 0,
    "unit": "per  100,000",
    "population": null,
    "notes": "All incidence rates were age-adjusted to the 2000 US\nstandard  population  and  reported  per  100,000  individuals",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2019",
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "The ARIMA APC model\nwas used to predict incidence with a 95% confidence interval of\nindividual metastatic diseases, and metastatic disease to specific\nsites, among ages 0 to 85 from 2019 to 2040",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2019",
    "value": 85,
    "unit": "%",
    "population": null,
    "notes": "The ARIMA APC model\nwas used to predict incidence with a 95% confidence interval of\nindividual metastatic diseases, and metastatic disease to specific\nsites, among ages 0 to 85 from 2019 to 2040",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2019",
    "value": 2019,
    "unit": "%",
    "population": null,
    "notes": "The ARIMA APC model\nwas used to predict incidence with a 95% confidence interval of\nindividual metastatic diseases, and metastatic disease to specific\nsites, among ages 0 to 85 from 2019 to 2040",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2019",
    "value": 2040,
    "unit": "%",
    "population": null,
    "notes": "The ARIMA APC model\nwas used to predict incidence with a 95% confidence interval of\nindividual metastatic diseases, and metastatic disease to specific\nsites, among ages 0 to 85 from 2019 to 2040",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 84,
    "unit": "year",
    "population": null,
    "notes": "For each\ncancer type, incidence by age from 0–84 and single calendar year\n(from 1988 to 2018) were directly obtained from SEER",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 1988,
    "unit": "year",
    "population": null,
    "notes": "For each\ncancer type, incidence by age from 0–84 and single calendar year\n(from 1988 to 2018) were directly obtained from SEER",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 2018,
    "unit": "year",
    "population": null,
    "notes": "For each\ncancer type, incidence by age from 0–84 and single calendar year\n(from 1988 to 2018) were directly obtained from SEER",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 1988,
    "unit": "cases",
    "population": null,
    "notes": "Joinpoint regression models\nwere employed to analyze long-term trends in metastatic cancer\nincidence from the original SEER data and the ARIMA predic-\ntions (1988–2040)",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1988",
    "value": 2040,
    "unit": "cases",
    "population": null,
    "notes": "Joinpoint regression models\nwere employed to analyze long-term trends in metastatic cancer\nincidence from the original SEER data and the ARIMA predic-\ntions (1988–2040)",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 53,
    "unit": "per  100,000",
    "population": null,
    "notes": "The incidence of\nmetastatic  disease  was  53  per  100,000  individuals",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 34,
    "unit": "per 100,000",
    "population": null,
    "notes": "The\nage–period–cohort  autoregressive  integrated  moving  average\n(ARIMA) model predicted that by 2040, there would be 12,285\npatients living with metastatic cancer leading to an incidence of\n34 per ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 4.17,
    "unit": "per 100,000",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 7.2,
    "unit": "per 100,000",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0,
    "unit": "count",
    "population": null,
    "notes": "The incidence of\nmetastatic  disease  was  53  per  100,000  individuals",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 285,
    "unit": "count",
    "population": null,
    "notes": "The\nage–period–cohort  autoregressive  integrated  moving  average\n(ARIMA) model predicted that by 2040, there would be 12,285\npatients living with metastatic cancer leading to an incidence of\n34 per ",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 0,
    "unit": "count",
    "population": null,
    "notes": "The\nage–period–cohort  autoregressive  integrated  moving  average\n(ARIMA) model predicted that by 2040, there would be 12,285\npatients living with metastatic cancer leading to an incidence of\n34 per ",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2015",
    "value": 6.85,
    "unit": "count",
    "population": null,
    "notes": "In 2015, metastatic cancers of the lung and\nbronchus, colon and rectum, and pancreas had incidences of 27.8,\n8.48, and 6.85 cases per 100,000 individuals, respectively",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2015",
    "value": 0,
    "unit": "count",
    "population": null,
    "notes": "In 2015, metastatic cancers of the lung and\nbronchus, colon and rectum, and pancreas had incidences of 27.8,\n8.48, and 6.85 cases per 100,000 individuals, respectively",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 0,
    "unit": "count",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 0,
    "unit": "count",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 0.7,
    "unit": "count",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 0,
    "unit": "count",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "The\nage–period–cohort  autoregressive  integrated  moving  average\n(ARIMA) model predicted that by 2040, there would be 12,285\npatients living with metastatic cancer leading to an incidence of\n34 per ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2015",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "In 2015, metastatic cancers of the lung and\nbronchus, colon and rectum, and pancreas had incidences of 27.8,\n8.48, and 6.85 cases per 100,000 individuals, respectively",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Figure3displays ARIMAfitted and predicted models of\nmetastatic cancer incidence to 2040",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2015",
    "value": 27.8,
    "unit": "per 100,000",
    "population": null,
    "notes": "In 2015, metastatic cancers of the lung and\nbronchus, colon and rectum, and pancreas had incidences of 27.8,\n8.48, and 6.85 cases per 100,000 individuals, respectively",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2015",
    "value": 8.48,
    "unit": "per 100,000",
    "population": null,
    "notes": "In 2015, metastatic cancers of the lung and\nbronchus, colon and rectum, and pancreas had incidences of 27.8,\n8.48, and 6.85 cases per 100,000 individuals, respectively",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2015",
    "value": 6.85,
    "unit": "per 100,000",
    "population": null,
    "notes": "In 2015, metastatic cancers of the lung and\nbronchus, colon and rectum, and pancreas had incidences of 27.8,\n8.48, and 6.85 cases per 100,000 individuals, respectively",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 7.8,
    "unit": "per 100,000",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 4.17,
    "unit": "per 100,000",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 7.2,
    "unit": "per 100,000",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 0.7,
    "unit": "per  100,000",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 0.7,
    "unit": "per  100,000",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 1.1,
    "unit": "per  100,000",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 0.4,
    "unit": "per  100,000",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 0.001,
    "unit": "per  100,000",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.45,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.04,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.87,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.032,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 1.66,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 1.4,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 1.9,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.001,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.4,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.1,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.6,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.001,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 2.53,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 2.4,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 2.7,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.001,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 1.84,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 1.24,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 2.45,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.001,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.41,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.89,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.07,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.089,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.4,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.86,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.07,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.091,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 1.02,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 2.13,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.11,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.076,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.61,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 1.27,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.06,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0.073,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 53,
    "unit": "per  100,000",
    "population": null,
    "notes": "The incidence of\nmetastatic  disease  was  53  per  100,000  individuals",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 100,
    "unit": "per  100,000",
    "population": null,
    "notes": "The incidence of\nmetastatic  disease  was  53  per  100,000  individuals",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 0,
    "unit": "per  100,000",
    "population": null,
    "notes": "The incidence of\nmetastatic  disease  was  53  per  100,000  individuals",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 2040,
    "unit": "per 100,000",
    "population": null,
    "notes": "The\nage–period–cohort  autoregressive  integrated  moving  average\n(ARIMA) model predicted that by 2040, there would be 12,285\npatients living with metastatic cancer leading to an incidence of\n34 per ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 12,
    "unit": "per 100,000",
    "population": null,
    "notes": "The\nage–period–cohort  autoregressive  integrated  moving  average\n(ARIMA) model predicted that by 2040, there would be 12,285\npatients living with metastatic cancer leading to an incidence of\n34 per ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 285,
    "unit": "per 100,000",
    "population": null,
    "notes": "The\nage–period–cohort  autoregressive  integrated  moving  average\n(ARIMA) model predicted that by 2040, there would be 12,285\npatients living with metastatic cancer leading to an incidence of\n34 per ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 34,
    "unit": "per 100,000",
    "population": null,
    "notes": "The\nage–period–cohort  autoregressive  integrated  moving  average\n(ARIMA) model predicted that by 2040, there would be 12,285\npatients living with metastatic cancer leading to an incidence of\n34 per ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 100,
    "unit": "per 100,000",
    "population": null,
    "notes": "The\nage–period–cohort  autoregressive  integrated  moving  average\n(ARIMA) model predicted that by 2040, there would be 12,285\npatients living with metastatic cancer leading to an incidence of\n34 per ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 0,
    "unit": "per 100,000",
    "population": null,
    "notes": "The\nage–period–cohort  autoregressive  integrated  moving  average\n(ARIMA) model predicted that by 2040, there would be 12,285\npatients living with metastatic cancer leading to an incidence of\n34 per ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2015",
    "value": 2015,
    "unit": "per 100,000",
    "population": null,
    "notes": "In 2015, metastatic cancers of the lung and\nbronchus, colon and rectum, and pancreas had incidences of 27.8,\n8.48, and 6.85 cases per 100,000 individuals, respectively",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2015",
    "value": 27,
    "unit": "per 100,000",
    "population": null,
    "notes": "In 2015, metastatic cancers of the lung and\nbronchus, colon and rectum, and pancreas had incidences of 27.8,\n8.48, and 6.85 cases per 100,000 individuals, respectively",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2015",
    "value": 48,
    "unit": "per 100,000",
    "population": null,
    "notes": "In 2015, metastatic cancers of the lung and\nbronchus, colon and rectum, and pancreas had incidences of 27.8,\n8.48, and 6.85 cases per 100,000 individuals, respectively",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2015",
    "value": 85,
    "unit": "per 100,000",
    "population": null,
    "notes": "In 2015, metastatic cancers of the lung and\nbronchus, colon and rectum, and pancreas had incidences of 27.8,\n8.48, and 6.85 cases per 100,000 individuals, respectively",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2015",
    "value": 100,
    "unit": "per 100,000",
    "population": null,
    "notes": "In 2015, metastatic cancers of the lung and\nbronchus, colon and rectum, and pancreas had incidences of 27.8,\n8.48, and 6.85 cases per 100,000 individuals, respectively",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2015",
    "value": 0,
    "unit": "per 100,000",
    "population": null,
    "notes": "In 2015, metastatic cancers of the lung and\nbronchus, colon and rectum, and pancreas had incidences of 27.8,\n8.48, and 6.85 cases per 100,000 individuals, respectively",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 2040,
    "unit": "per 100,000",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 80,
    "unit": "per 100,000",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 17,
    "unit": "per 100,000",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 100,
    "unit": "per 100,000",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 0,
    "unit": "per 100,000",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 20,
    "unit": "per 100,000",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 100,
    "unit": "per 100,000",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 0,
    "unit": "per 100,000",
    "population": null,
    "notes": "By 2040,\nthe predicted incidences of lung and bronchus and colon and\nrectum decreased to 7.80 and 4.17 per 100,000 individuals,\nrespectively, and the incidence of pancreatic cancer increased to\n7.20 p",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2040",
    "value": 2040,
    "unit": "cases",
    "population": null,
    "notes": "Figure3displays ARIMAfitted and predicted models of\nmetastatic cancer incidence to 2040",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 70,
    "unit": "per  100,000",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 100,
    "unit": "per  100,000",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 0,
    "unit": "per  100,000",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 70,
    "unit": "per  100,000",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 95,
    "unit": "per  100,000",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 10,
    "unit": "per  100,000",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 40,
    "unit": "per  100,000",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 1,
    "unit": "per  100,000",
    "population": null,
    "notes": "Overall incidence of metastatic cancer is predicted to decrease\nat  a  rate  of  0.70  cases  per  100,000  individuals  per  year\n(APC=−0.70, 95% CI [−1.10,−0.40];p< 0.001)",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 45,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 4,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 87,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 32,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 66,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 40,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 90,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 1,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 40,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 10,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 60,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 1,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 53,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 40,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 70,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 1,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 84,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 24,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 45,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 1,
    "unit": "%",
    "population": null,
    "notes": "Metastatic\ncancers  predicted  to  increase  in  incidence  are  esophageal\n(APC=0.45, 95% CI [0.04, 0.87];p=0.032), pancreatic (APC=\n1.66, 95% CI [1.40, 1.90];p< 0.001), kidney (APC=0.40, 95% CI\n[0.1",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 41,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 89,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 7,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 89,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 40,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 86,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 7,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 91,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 2,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 13,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 11,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 76,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 61,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 95,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 27,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 6,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 73,
    "unit": "%",
    "population": null,
    "notes": "Metastatic cancers not projected to\nchange  significantly  in  incidence  include  colon  and  rectal\n(APC=−0.41, 95% CI [−0.89, 0.07];p=0.089), corpus uteri\n(APC=−0.40, 95% CI [−0.86,−0.07];p=0.091),",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 60,
    "unit": "cases",
    "population": null,
    "notes": "When these\ndata are stratified by age, the incidence of each metastatic cancer\nis much greater for patients above age 60 (Supplemental Fig",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 46.7,
    "unit": "%",
    "population": null,
    "notes": "Our\npredictions indicate from 2018 to 2040 the APC in incidence of\nmetastases in the US will decrease by 0.70 per 100,000 individuals,\nand long-term survivorship will increase by 46.7%",
    "pageHint": 3,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 0.7,
    "unit": "per 100,000",
    "population": null,
    "notes": "Our\npredictions indicate from 2018 to 2040 the APC in incidence of\nmetastases in the US will decrease by 0.70 per 100,000 individuals,\nand long-term survivorship will increase by 46.7%",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 0,
    "unit": "count",
    "population": null,
    "notes": "Our\npredictions indicate from 2018 to 2040 the APC in incidence of\nmetastases in the US will decrease by 0.70 per 100,000 individuals,\nand long-term survivorship will increase by 46.7%",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Our\npredictions indicate from 2018 to 2040 the APC in incidence of\nmetastases in the US will decrease by 0.70 per 100,000 individuals,\nand long-term survivorship will increase by 46.7%",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Our\npredictions indicate from 2018 to 2040 the APC in incidence of\nmetastases in the US will decrease by 0.70 per 100,000 individuals,\nand long-term survivorship will increase by 46.7%",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 0.7,
    "unit": "per 100,000",
    "population": null,
    "notes": "Our\npredictions indicate from 2018 to 2040 the APC in incidence of\nmetastases in the US will decrease by 0.70 per 100,000 individuals,\nand long-term survivorship will increase by 46.7%",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 46.7,
    "unit": "per 100,000",
    "population": null,
    "notes": "Our\npredictions indicate from 2018 to 2040 the APC in incidence of\nmetastases in the US will decrease by 0.70 per 100,000 individuals,\nand long-term survivorship will increase by 46.7%",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 2018,
    "unit": "per 100,000",
    "population": null,
    "notes": "Our\npredictions indicate from 2018 to 2040 the APC in incidence of\nmetastases in the US will decrease by 0.70 per 100,000 individuals,\nand long-term survivorship will increase by 46.7%",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 2040,
    "unit": "per 100,000",
    "population": null,
    "notes": "Our\npredictions indicate from 2018 to 2040 the APC in incidence of\nmetastases in the US will decrease by 0.70 per 100,000 individuals,\nand long-term survivorship will increase by 46.7%",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 70,
    "unit": "per 100,000",
    "population": null,
    "notes": "Our\npredictions indicate from 2018 to 2040 the APC in incidence of\nmetastases in the US will decrease by 0.70 per 100,000 individuals,\nand long-term survivorship will increase by 46.7%",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 100,
    "unit": "per 100,000",
    "population": null,
    "notes": "Our\npredictions indicate from 2018 to 2040 the APC in incidence of\nmetastases in the US will decrease by 0.70 per 100,000 individuals,\nand long-term survivorship will increase by 46.7%",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 0,
    "unit": "per 100,000",
    "population": null,
    "notes": "Our\npredictions indicate from 2018 to 2040 the APC in incidence of\nmetastases in the US will decrease by 0.70 per 100,000 individuals,\nand long-term survivorship will increase by 46.7%",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2018",
    "value": 46,
    "unit": "per 100,000",
    "population": null,
    "notes": "Our\npredictions indicate from 2018 to 2040 the APC in incidence of\nmetastases in the US will decrease by 0.70 per 100,000 individuals,\nand long-term survivorship will increase by 46.7%",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "rate",
    "yearOrRange": null,
    "value": 75,
    "unit": "cases",
    "population": null,
    "notes": "Similarly, ourfindings\ndemonstrated that the greatest incidences of metastatic cancers in\nindividuals aged over 75, suggesting these populations should be\nemphasized in ongoing surveillance efforts",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": null,
    "value": 0,
    "unit": "count",
    "population": null,
    "notes": "3 Incidence of metastatic cancer.Thefigure shows population adjusted average incidence of metastatic cancers reported per 100,000 individuals",
    "pageHint": 4,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 30,
    "unit": "cases",
    "population": null,
    "notes": "The present work also forecasts a sharp decline in lung cancer\nincidence, similar to other population based studies\n30–32",
    "pageHint": 4,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 32,
    "unit": "cases",
    "population": null,
    "notes": "The present work also forecasts a sharp decline in lung cancer\nincidence, similar to other population based studies\n30–32",
    "pageHint": 4,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": null,
    "value": 100,
    "unit": "per 100,000",
    "population": null,
    "notes": "3 Incidence of metastatic cancer.Thefigure shows population adjusted average incidence of metastatic cancers reported per 100,000 individuals",
    "pageHint": 4,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": null,
    "value": 0,
    "unit": "per 100,000",
    "population": null,
    "notes": "3 Incidence of metastatic cancer.Thefigure shows population adjusted average incidence of metastatic cancers reported per 100,000 individuals",
    "pageHint": 4,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1970",
    "value": 38,
    "unit": "cases",
    "population": null,
    "notes": "found that from the 1970s to 2000s, the incidence of esophageal\nadenocarcinoma doubled, while the incidence of squamous cell\ncarcinoma decreased\n38",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 23,
    "unit": "cases",
    "population": null,
    "notes": "Body size and renal cell cancer incidence in a large US\ncohort study.Am",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1973",
    "value": 9,
    "unit": "%",
    "population": "US population",
    "notes": "The SEER 9 regis-\ntries have provided incidence data since 1973 on approx-\nimately 9% of the US population, but they include only \ncancer case numbers, not population or incidence rates, by \nrace and ",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2000",
    "value": 27.8,
    "unit": "%",
    "population": null,
    "notes": "8,9\n\nSEER  18  expanded  to  18  cancer  incidence  registries  in  \n2000 and included approximately 27.8% of the US pop-\nulation in 2010",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": 36.7,
    "unit": "%",
    "population": "US population",
    "notes": "We  analyzed  age-  \nadjusted,  delay-  adjusted  invasive  breast  cancer  incidence  \nrates in females for the years 2014- 2017 by using data from \nSEER 21, which includes 21 registries representing",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 75,
    "unit": "years",
    "population": null,
    "notes": "As  in  Stapleton  et  al,\n3\n  we  included  only  invasive  \nbreast  cancers  and  determined  the  percentage  of  inva-\nsive breast cancer cases at each age from 40 to 75 years in \neach  cohort",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": 75,
    "unit": "years",
    "population": null,
    "notes": "We  used  SEER  21  data  from  2014-  2017  for  fe-\nmales aged 40 to 75 years to determine the median age, \ninterquartile  range,  and  mode  (ie,  peak  count)  age  of  \ninvasive  breast  cancer  ",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1973",
    "value": null,
    "unit": "year",
    "population": "US population",
    "notes": "The SEER 9 regis-\ntries have provided incidence data since 1973 on approx-\nimately 9% of the US population, but they include only \ncancer case numbers, not population or incidence rates, by \nrace and ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2000",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "8,9\n\nSEER  18  expanded  to  18  cancer  incidence  registries  in  \n2000 and included approximately 27.8% of the US pop-\nulation in 2010",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2000",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "8,9\n\nSEER  18  expanded  to  18  cancer  incidence  registries  in  \n2000 and included approximately 27.8% of the US pop-\nulation in 2010",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": null,
    "unit": "year",
    "population": "US population",
    "notes": "We  analyzed  age-  \nadjusted,  delay-  adjusted  invasive  breast  cancer  incidence  \nrates in females for the years 2014- 2017 by using data from \nSEER 21, which includes 21 registries representing",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": null,
    "unit": "year",
    "population": "US population",
    "notes": "We  analyzed  age-  \nadjusted,  delay-  adjusted  invasive  breast  cancer  incidence  \nrates in females for the years 2014- 2017 by using data from \nSEER 21, which includes 21 registries representing",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "We  used  SEER  21  data  from  2014-  2017  for  fe-\nmales aged 40 to 75 years to determine the median age, \ninterquartile  range,  and  mode  (ie,  peak  count)  age  of  \ninvasive  breast  cancer  ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "We  used  SEER  21  data  from  2014-  2017  for  fe-\nmales aged 40 to 75 years to determine the median age, \ninterquartile  range,  and  mode  (ie,  peak  count)  age  of  \ninvasive  breast  cancer  ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2000",
    "value": 27.8,
    "unit": "%",
    "population": null,
    "notes": "8,9\n\nSEER  18  expanded  to  18  cancer  incidence  registries  in  \n2000 and included approximately 27.8% of the US pop-\nulation in 2010",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": 36.7,
    "unit": "years",
    "population": "US population",
    "notes": "We  analyzed  age-  \nadjusted,  delay-  adjusted  invasive  breast  cancer  incidence  \nrates in females for the years 2014- 2017 by using data from \nSEER 21, which includes 21 registries representing",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 8.3,
    "unit": "cases",
    "population": null,
    "notes": "8,11\n Using SEER*Stat software \n(versions 8.3.6 and 8.3.8; National Cancer Institute), we \nexamined invasive breast cancer incidence rates and mor-\ntality  rates  by  the  following  race  and  ethnic",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 8.3,
    "unit": "cases",
    "population": null,
    "notes": "8,11\n Using SEER*Stat software \n(versions 8.3.6 and 8.3.8; National Cancer Institute), we \nexamined invasive breast cancer incidence rates and mor-\ntality  rates  by  the  following  race  and  ethnic",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "1973",
    "value": 1973,
    "unit": "%",
    "population": "US population",
    "notes": "The SEER 9 regis-\ntries have provided incidence data since 1973 on approx-\nimately 9% of the US population, but they include only \ncancer case numbers, not population or incidence rates, by \nrace and ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2000",
    "value": 18,
    "unit": "%",
    "population": null,
    "notes": "8,9\n\nSEER  18  expanded  to  18  cancer  incidence  registries  in  \n2000 and included approximately 27.8% of the US pop-\nulation in 2010",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2000",
    "value": 18,
    "unit": "%",
    "population": null,
    "notes": "8,9\n\nSEER  18  expanded  to  18  cancer  incidence  registries  in  \n2000 and included approximately 27.8% of the US pop-\nulation in 2010",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2000",
    "value": 2000,
    "unit": "%",
    "population": null,
    "notes": "8,9\n\nSEER  18  expanded  to  18  cancer  incidence  registries  in  \n2000 and included approximately 27.8% of the US pop-\nulation in 2010",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2000",
    "value": 27,
    "unit": "%",
    "population": null,
    "notes": "8,9\n\nSEER  18  expanded  to  18  cancer  incidence  registries  in  \n2000 and included approximately 27.8% of the US pop-\nulation in 2010",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2000",
    "value": 2010,
    "unit": "%",
    "population": null,
    "notes": "8,9\n\nSEER  18  expanded  to  18  cancer  incidence  registries  in  \n2000 and included approximately 27.8% of the US pop-\nulation in 2010",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 10,
    "unit": "cases",
    "population": "US population",
    "notes": "10\n Given the importance of their findings \nand  their  implications  concerning  racial  disparities,  we  \nthought  it  worthwhile  to  revisit  breast  cancer  incidence  \ntrends  using  more  rece",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": 2014,
    "unit": "years",
    "population": "US population",
    "notes": "We  analyzed  age-  \nadjusted,  delay-  adjusted  invasive  breast  cancer  incidence  \nrates in females for the years 2014- 2017 by using data from \nSEER 21, which includes 21 registries representing",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": 2017,
    "unit": "years",
    "population": "US population",
    "notes": "We  analyzed  age-  \nadjusted,  delay-  adjusted  invasive  breast  cancer  incidence  \nrates in females for the years 2014- 2017 by using data from \nSEER 21, which includes 21 registries representing",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": 21,
    "unit": "years",
    "population": "US population",
    "notes": "We  analyzed  age-  \nadjusted,  delay-  adjusted  invasive  breast  cancer  incidence  \nrates in females for the years 2014- 2017 by using data from \nSEER 21, which includes 21 registries representing",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": 21,
    "unit": "years",
    "population": "US population",
    "notes": "We  analyzed  age-  \nadjusted,  delay-  adjusted  invasive  breast  cancer  incidence  \nrates in females for the years 2014- 2017 by using data from \nSEER 21, which includes 21 registries representing",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": 36,
    "unit": "years",
    "population": "US population",
    "notes": "We  analyzed  age-  \nadjusted,  delay-  adjusted  invasive  breast  cancer  incidence  \nrates in females for the years 2014- 2017 by using data from \nSEER 21, which includes 21 registries representing",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 11,
    "unit": "cases",
    "population": null,
    "notes": "8,11\n Using SEER*Stat software \n(versions 8.3.6 and 8.3.8; National Cancer Institute), we \nexamined invasive breast cancer incidence rates and mor-\ntality  rates  by  the  following  race  and  ethnic",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 40,
    "unit": "years",
    "population": null,
    "notes": "As  in  Stapleton  et  al,\n3\n  we  included  only  invasive  \nbreast  cancers  and  determined  the  percentage  of  inva-\nsive breast cancer cases at each age from 40 to 75 years in \neach  cohort",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 75,
    "unit": "years",
    "population": null,
    "notes": "As  in  Stapleton  et  al,\n3\n  we  included  only  invasive  \nbreast  cancers  and  determined  the  percentage  of  inva-\nsive breast cancer cases at each age from 40 to 75 years in \neach  cohort",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": 21,
    "unit": "years",
    "population": null,
    "notes": "We  used  SEER  21  data  from  2014-  2017  for  fe-\nmales aged 40 to 75 years to determine the median age, \ninterquartile  range,  and  mode  (ie,  peak  count)  age  of  \ninvasive  breast  cancer  ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": 2014,
    "unit": "years",
    "population": null,
    "notes": "We  used  SEER  21  data  from  2014-  2017  for  fe-\nmales aged 40 to 75 years to determine the median age, \ninterquartile  range,  and  mode  (ie,  peak  count)  age  of  \ninvasive  breast  cancer  ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": 2017,
    "unit": "years",
    "population": null,
    "notes": "We  used  SEER  21  data  from  2014-  2017  for  fe-\nmales aged 40 to 75 years to determine the median age, \ninterquartile  range,  and  mode  (ie,  peak  count)  age  of  \ninvasive  breast  cancer  ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": 40,
    "unit": "years",
    "population": null,
    "notes": "We  used  SEER  21  data  from  2014-  2017  for  fe-\nmales aged 40 to 75 years to determine the median age, \ninterquartile  range,  and  mode  (ie,  peak  count)  age  of  \ninvasive  breast  cancer  ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2014",
    "value": 75,
    "unit": "years",
    "population": null,
    "notes": "We  used  SEER  21  data  from  2014-  2017  for  fe-\nmales aged 40 to 75 years to determine the median age, \ninterquartile  range,  and  mode  (ie,  peak  count)  age  of  \ninvasive  breast  cancer  ",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2017",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:  Incidence—  SEER  9  Regs  Research  Data,  Nov  2017  Sub  \n(1973- 2015) <Katrina/Rita   Population   Adjustment>— Linked    to \nCounty Attributes— Total U.S., 1969- 2016 Count",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2017",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:  Incidence—  SEER  9  Regs  Research  Data,  Nov  2017  Sub  \n(1973- 2015) <Katrina/Rita   Population   Adjustment>— Linked    to \nCounty Attributes— Total U.S., 1969- 2016 Count",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2017",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:  Incidence—  SEER  9  Regs  Research  Data,  Nov  2017  Sub  \n(1973- 2015) <Katrina/Rita   Population   Adjustment>— Linked    to \nCounty Attributes— Total U.S., 1969- 2016 Count",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2019",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:  Incidence—  SEER  Research  Data,  18  Registries,  Nov  2019  \nSub  (2000-  2017)—  Linked  to  County  Attributes—  Time  Dependent  \n(1990- 2017) Income/Rurality, 1969- 2018 ",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2019",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:  Incidence—  SEER  Research  Data,  18  Registries,  Nov  2019  \nSub  (2000-  2017)—  Linked  to  County  Attributes—  Time  Dependent  \n(1990- 2017) Income/Rurality, 1969- 2018 ",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2019",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:  Incidence—  SEER  Research  Data,  18  Registries,  Nov  2019  \nSub  (2000-  2017)—  Linked  to  County  Attributes—  Time  Dependent  \n(1990- 2017) Income/Rurality, 1969- 2018 ",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2019",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:   Incidence—   SEER   Research   Limited-   Field   Data   With   \nDelay-  Adjustment,  21  Registries,  Malignant  Only,  Nov  2019  Sub  \n(2000-    2017)—    Linked    to    Co",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2019",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:   Incidence—   SEER   Research   Limited-   Field   Data   With   \nDelay-  Adjustment,  21  Registries,  Malignant  Only,  Nov  2019  Sub  \n(2000-    2017)—    Linked    to    Co",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2019",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:   Incidence—   SEER   Research   Limited-   Field   Data   With   \nDelay-  Adjustment,  21  Registries,  Malignant  Only,  Nov  2019  Sub  \n(2000-    2017)—    Linked    to    Co",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2017",
    "value": 2017,
    "unit": "cases",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:  Incidence—  SEER  9  Regs  Research  Data,  Nov  2017  Sub  \n(1973- 2015) <Katrina/Rita   Population   Adjustment>— Linked    to \nCounty Attributes— Total U.S., 1969- 2016 Count",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2017",
    "value": 1973,
    "unit": "cases",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:  Incidence—  SEER  9  Regs  Research  Data,  Nov  2017  Sub  \n(1973- 2015) <Katrina/Rita   Population   Adjustment>— Linked    to \nCounty Attributes— Total U.S., 1969- 2016 Count",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2017",
    "value": 2015,
    "unit": "cases",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:  Incidence—  SEER  9  Regs  Research  Data,  Nov  2017  Sub  \n(1973- 2015) <Katrina/Rita   Population   Adjustment>— Linked    to \nCounty Attributes— Total U.S., 1969- 2016 Count",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2019",
    "value": 18,
    "unit": "cases",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:  Incidence—  SEER  Research  Data,  18  Registries,  Nov  2019  \nSub  (2000-  2017)—  Linked  to  County  Attributes—  Time  Dependent  \n(1990- 2017) Income/Rurality, 1969- 2018 ",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2019",
    "value": 2019,
    "unit": "cases",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:  Incidence—  SEER  Research  Data,  18  Registries,  Nov  2019  \nSub  (2000-  2017)—  Linked  to  County  Attributes—  Time  Dependent  \n(1990- 2017) Income/Rurality, 1969- 2018 ",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2019",
    "value": 2000,
    "unit": "cases",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:  Incidence—  SEER  Research  Data,  18  Registries,  Nov  2019  \nSub  (2000-  2017)—  Linked  to  County  Attributes—  Time  Dependent  \n(1990- 2017) Income/Rurality, 1969- 2018 ",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2019",
    "value": 2017,
    "unit": "cases",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:  Incidence—  SEER  Research  Data,  18  Registries,  Nov  2019  \nSub  (2000-  2017)—  Linked  to  County  Attributes—  Time  Dependent  \n(1990- 2017) Income/Rurality, 1969- 2018 ",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2019",
    "value": 21,
    "unit": "cases",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:   Incidence—   SEER   Research   Limited-   Field   Data   With   \nDelay-  Adjustment,  21  Registries,  Malignant  Only,  Nov  2019  Sub  \n(2000-    2017)—    Linked    to    Co",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2019",
    "value": 2019,
    "unit": "cases",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:   Incidence—   SEER   Research   Limited-   Field   Data   With   \nDelay-  Adjustment,  21  Registries,  Malignant  Only,  Nov  2019  Sub  \n(2000-    2017)—    Linked    to    Co",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2019",
    "value": 2000,
    "unit": "cases",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:   Incidence—   SEER   Research   Limited-   Field   Data   With   \nDelay-  Adjustment,  21  Registries,  Malignant  Only,  Nov  2019  Sub  \n(2000-    2017)—    Linked    to    Co",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-005",
    "filename": "Hendrick_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "2019",
    "value": 2017,
    "unit": "cases",
    "population": null,
    "notes": "SEER*Stat  \nDatabase:   Incidence—   SEER   Research   Limited-   Field   Data   With   \nDelay-  Adjustment,  21  Registries,  Malignant  Only,  Nov  2019  Sub  \n(2000-    2017)—    Linked    to    Co",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2045",
    "value": 3.4,
    "unit": "%",
    "population": null,
    "notes": "The  patients  with  HR\n+\n/HER2\n−\n  subtype  harbored  \nthe   highest   incidence   proportion   (3.4%   of   the   entire   \nstudy  population,  42.4%  of  the  metastatic  subgroup)  and  \n 20457634",
    "pageHint": 1,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2045",
    "value": 42.4,
    "unit": "%",
    "population": null,
    "notes": "The  patients  with  HR\n+\n/HER2\n−\n  subtype  harbored  \nthe   highest   incidence   proportion   (3.4%   of   the   entire   \nstudy  population,  42.4%  of  the  metastatic  subgroup)  and  \n 20457634",
    "pageHint": 1,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2045",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "The  patients  with  HR\n+\n/HER2\n−\n  subtype  harbored  \nthe   highest   incidence   proportion   (3.4%   of   the   entire   \nstudy  population,  42.4%  of  the  metastatic  subgroup)  and  \n 20457634",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 3.4,
    "unit": "cases",
    "population": null,
    "notes": "Results\nThe  absolute  quantity  and  incidence  proportion  of  our  \ncohort according to molecular subtypes appear in Table 1",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2045",
    "value": 3.4,
    "unit": "%",
    "population": null,
    "notes": "The  patients  with  HR\n+\n/HER2\n−\n  subtype  harbored  \nthe   highest   incidence   proportion   (3.4%   of   the   entire   \nstudy  population,  42.4%  of  the  metastatic  subgroup)  and  \n 20457634",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2045",
    "value": 42.4,
    "unit": "%",
    "population": null,
    "notes": "The  patients  with  HR\n+\n/HER2\n−\n  subtype  harbored  \nthe   highest   incidence   proportion   (3.4%   of   the   entire   \nstudy  population,  42.4%  of  the  metastatic  subgroup)  and  \n 20457634",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2045",
    "value": 10.1002,
    "unit": "%",
    "population": null,
    "notes": "The  patients  with  HR\n+\n/HER2\n−\n  subtype  harbored  \nthe   highest   incidence   proportion   (3.4%   of   the   entire   \nstudy  population,  42.4%  of  the  metastatic  subgroup)  and  \n 20457634",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2045",
    "value": 42,
    "unit": "%",
    "population": null,
    "notes": "The  patients  with  HR\n+\n/HER2\n−\n  subtype  harbored  \nthe   highest   incidence   proportion   (3.4%   of   the   entire   \nstudy  population,  42.4%  of  the  metastatic  subgroup)  and  \n 20457634",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2045",
    "value": 20457634,
    "unit": "%",
    "population": null,
    "notes": "The  patients  with  HR\n+\n/HER2\n−\n  subtype  harbored  \nthe   highest   incidence   proportion   (3.4%   of   the   entire   \nstudy  population,  42.4%  of  the  metastatic  subgroup)  and  \n 20457634",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2045",
    "value": 2018,
    "unit": "%",
    "population": null,
    "notes": "The  patients  with  HR\n+\n/HER2\n−\n  subtype  harbored  \nthe   highest   incidence   proportion   (3.4%   of   the   entire   \nstudy  population,  42.4%  of  the  metastatic  subgroup)  and  \n 20457634",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2045",
    "value": 10,
    "unit": "%",
    "population": null,
    "notes": "The  patients  with  HR\n+\n/HER2\n−\n  subtype  harbored  \nthe   highest   incidence   proportion   (3.4%   of   the   entire   \nstudy  population,  42.4%  of  the  metastatic  subgroup)  and  \n 20457634",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": "2045",
    "value": 1002,
    "unit": "%",
    "population": null,
    "notes": "The  patients  with  HR\n+\n/HER2\n−\n  subtype  harbored  \nthe   highest   incidence   proportion   (3.4%   of   the   entire   \nstudy  population,  42.4%  of  the  metastatic  subgroup)  and  \n 20457634",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 8.5,
    "unit": "%",
    "population": null,
    "notes": "Their  results  indicated  that  \nthe  incidence  of  lung  metastasis  as  first  distant  metastases  \nwas  8.5%,  16.3%,  22.9%,  20.8%,  respectively,  in  luminal  \nA,  luminal  B,  HER2\n+\n-  enr",
    "pageHint": 5,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 16.3,
    "unit": "%",
    "population": null,
    "notes": "Their  results  indicated  that  \nthe  incidence  of  lung  metastasis  as  first  distant  metastases  \nwas  8.5%,  16.3%,  22.9%,  20.8%,  respectively,  in  luminal  \nA,  luminal  B,  HER2\n+\n-  enr",
    "pageHint": 5,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 22.9,
    "unit": "%",
    "population": null,
    "notes": "Their  results  indicated  that  \nthe  incidence  of  lung  metastasis  as  first  distant  metastases  \nwas  8.5%,  16.3%,  22.9%,  20.8%,  respectively,  in  luminal  \nA,  luminal  B,  HER2\n+\n-  enr",
    "pageHint": 5,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 20.8,
    "unit": "%",
    "population": null,
    "notes": "Their  results  indicated  that  \nthe  incidence  of  lung  metastasis  as  first  distant  metastases  \nwas  8.5%,  16.3%,  22.9%,  20.8%,  respectively,  in  luminal  \nA,  luminal  B,  HER2\n+\n-  enr",
    "pageHint": 5,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": null,
    "yearOrRange": "2032",
    "value": 2.7,
    "unit": "years",
    "population": null,
    "notes": "[14]  reported  that  234  cases  of  distant  metas-\ntases   occurred   in   2032   cases   of   breast   cancer   patients   \nafter  follow-  up  of  2.7  years",
    "pageHint": 5,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": null,
    "yearOrRange": "2032",
    "value": 234,
    "unit": "count",
    "population": null,
    "notes": "[14]  reported  that  234  cases  of  distant  metas-\ntases   occurred   in   2032   cases   of   breast   cancer   patients   \nafter  follow-  up  of  2.7  years",
    "pageHint": 5,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": null,
    "yearOrRange": "2032",
    "value": 2032,
    "unit": "count",
    "population": null,
    "notes": "[14]  reported  that  234  cases  of  distant  metas-\ntases   occurred   in   2032   cases   of   breast   cancer   patients   \nafter  follow-  up  of  2.7  years",
    "pageHint": 5,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": null,
    "yearOrRange": "2032",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "[14]  reported  that  234  cases  of  distant  metas-\ntases   occurred   in   2032   cases   of   breast   cancer   patients   \nafter  follow-  up  of  2.7  years",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": null,
    "yearOrRange": "2032",
    "value": 2.7,
    "unit": "years",
    "population": null,
    "notes": "[14]  reported  that  234  cases  of  distant  metas-\ntases   occurred   in   2032   cases   of   breast   cancer   patients   \nafter  follow-  up  of  2.7  years",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 8.5,
    "unit": "%",
    "population": null,
    "notes": "Their  results  indicated  that  \nthe  incidence  of  lung  metastasis  as  first  distant  metastases  \nwas  8.5%,  16.3%,  22.9%,  20.8%,  respectively,  in  luminal  \nA,  luminal  B,  HER2\n+\n-  enr",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 16.3,
    "unit": "%",
    "population": null,
    "notes": "Their  results  indicated  that  \nthe  incidence  of  lung  metastasis  as  first  distant  metastases  \nwas  8.5%,  16.3%,  22.9%,  20.8%,  respectively,  in  luminal  \nA,  luminal  B,  HER2\n+\n-  enr",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 22.9,
    "unit": "%",
    "population": null,
    "notes": "Their  results  indicated  that  \nthe  incidence  of  lung  metastasis  as  first  distant  metastases  \nwas  8.5%,  16.3%,  22.9%,  20.8%,  respectively,  in  luminal  \nA,  luminal  B,  HER2\n+\n-  enr",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 20.8,
    "unit": "%",
    "population": null,
    "notes": "Their  results  indicated  that  \nthe  incidence  of  lung  metastasis  as  first  distant  metastases  \nwas  8.5%,  16.3%,  22.9%,  20.8%,  respectively,  in  luminal  \nA,  luminal  B,  HER2\n+\n-  enr",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": null,
    "yearOrRange": "2032",
    "value": 14,
    "unit": "years",
    "population": null,
    "notes": "[14]  reported  that  234  cases  of  distant  metas-\ntases   occurred   in   2032   cases   of   breast   cancer   patients   \nafter  follow-  up  of  2.7  years",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": null,
    "yearOrRange": "2032",
    "value": 234,
    "unit": "years",
    "population": null,
    "notes": "[14]  reported  that  234  cases  of  distant  metas-\ntases   occurred   in   2032   cases   of   breast   cancer   patients   \nafter  follow-  up  of  2.7  years",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": null,
    "yearOrRange": "2032",
    "value": 2032,
    "unit": "years",
    "population": null,
    "notes": "[14]  reported  that  234  cases  of  distant  metas-\ntases   occurred   in   2032   cases   of   breast   cancer   patients   \nafter  follow-  up  of  2.7  years",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 16,
    "unit": "%",
    "population": null,
    "notes": "Their  results  indicated  that  \nthe  incidence  of  lung  metastasis  as  first  distant  metastases  \nwas  8.5%,  16.3%,  22.9%,  20.8%,  respectively,  in  luminal  \nA,  luminal  B,  HER2\n+\n-  enr",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 22,
    "unit": "%",
    "population": null,
    "notes": "Their  results  indicated  that  \nthe  incidence  of  lung  metastasis  as  first  distant  metastases  \nwas  8.5%,  16.3%,  22.9%,  20.8%,  respectively,  in  luminal  \nA,  luminal  B,  HER2\n+\n-  enr",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 20,
    "unit": "%",
    "population": null,
    "notes": "Their  results  indicated  that  \nthe  incidence  of  lung  metastasis  as  first  distant  metastases  \nwas  8.5%,  16.3%,  22.9%,  20.8%,  respectively,  in  luminal  \nA,  luminal  B,  HER2\n+\n-  enr",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 14,
    "unit": "cases",
    "population": null,
    "notes": "One  of  the  advantages  of  these  studies  was  the  pro-\nvision  of  information  on  the  cumulative  incidence  of  lung  \nmetastases  during  the  natural  course  of  the  disease",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 25,
    "unit": "cases",
    "population": null,
    "notes": "Although  young  women  were  more  likely  to  develop  more  \naggressive  breast  cancer  subtypes  and  more  advanced  dis-\neases   [25–27],   it   revealed   a   higher   incidence   of   lung   ",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 27,
    "unit": "cases",
    "population": null,
    "notes": "Although  young  women  were  more  likely  to  develop  more  \naggressive  breast  cancer  subtypes  and  more  advanced  dis-\neases   [25–27],   it   revealed   a   higher   incidence   of   lung   ",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": null,
    "value": 10,
    "unit": "cases",
    "population": null,
    "notes": "8, 9), has been used to reconstruct\nprevalence of recurrent cancer in Australia (10)",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": null,
    "value": 11,
    "unit": "cases",
    "population": null,
    "notes": "The method\nhas also been used to estimate the prevalence of breast cancer\nsurvivors in states within the United States (11) when cancer\nincidence data are not available over the long-term",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": null,
    "value": 1.2,
    "unit": "cases",
    "population": null,
    "notes": "We also\nperformed sensitivity analyses and provided prevalence estimates\nusing a lower and a higher relative risk adjustment of 1.2 and 1.5,\nrespectively",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": null,
    "value": 1.5,
    "unit": "cases",
    "population": null,
    "notes": "We also\nperformed sensitivity analyses and provided prevalence estimates\nusing a lower and a higher relative risk adjustment of 1.2 and 1.5,\nrespectively",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": 4,
    "unit": "%",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": 17,
    "unit": "%",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": 31,
    "unit": "%",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 40,
    "unit": "%",
    "population": null,
    "notes": "Although the largestmajority\nof prevalent cases are women who have been living with meta-\nstatic disease for 2 years or less (40%), one third (34%) have lived\nfor 5 years or more with MBC (Fig",
    "pageHint": 3,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 34,
    "unit": "%",
    "population": null,
    "notes": "Although the largestmajority\nof prevalent cases are women who have been living with meta-\nstatic disease for 2 years or less (40%), one third (34%) have lived\nfor 5 years or more with MBC (Fig",
    "pageHint": 3,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 2,
    "unit": "years",
    "population": null,
    "notes": "Although the largestmajority\nof prevalent cases are women who have been living with meta-\nstatic disease for 2 years or less (40%), one third (34%) have lived\nfor 5 years or more with MBC (Fig",
    "pageHint": 3,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 5,
    "unit": "years",
    "population": null,
    "notes": "Although the largestmajority\nof prevalent cases are women who have been living with meta-\nstatic disease for 2 years or less (40%), one third (34%) have lived\nfor 5 years or more with MBC (Fig",
    "pageHint": 3,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 26,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017811\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 809,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017811\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Estimates and projections of MBC\nprevalence in the United States from\n1990 to 2020 (gray bars)",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Estimates and projections of MBC\nprevalence in the United States from\n1990 to 2020 (gray bars)",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": null,
    "unit": "year",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017811\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": 1990,
    "unit": "%",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": 2000,
    "unit": "%",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": 17,
    "unit": "%",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": 2000,
    "unit": "%",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": 2010,
    "unit": "%",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": 31,
    "unit": "%",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": 2020,
    "unit": "%",
    "population": null,
    "notes": "Figure 1 shows that, based on our calculations, MBC prevalence\nin terms of the number of women living with MBC increased 4%\nfrom 1990 to 2000, 17% from 2000 to 2010, and is projected to\nincrease by 31",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 40,
    "unit": "years",
    "population": null,
    "notes": "Although the largestmajority\nof prevalent cases are women who have been living with meta-\nstatic disease for 2 years or less (40%), one third (34%) have lived\nfor 5 years or more with MBC (Fig",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": null,
    "yearOrRange": null,
    "value": 34,
    "unit": "years",
    "population": null,
    "notes": "Although the largestmajority\nof prevalent cases are women who have been living with meta-\nstatic disease for 2 years or less (40%), one third (34%) have lived\nfor 5 years or more with MBC (Fig",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": 1990,
    "unit": "cases",
    "population": null,
    "notes": "Estimates and projections of MBC\nprevalence in the United States from\n1990 to 2020 (gray bars)",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1990",
    "value": 2020,
    "unit": "cases",
    "population": null,
    "notes": "Estimates and projections of MBC\nprevalence in the United States from\n1990 to 2020 (gray bars)",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 26,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017811\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 2017811,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017811\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 26,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017811\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 809,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017811\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 2282958,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017811\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 809,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017811\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 1,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017811\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 2026,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017811\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 3,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "incidence",
    "yearOrRange": null,
    "value": 19,
    "unit": "cases",
    "population": null,
    "notes": "A study\nusing SEER data (19) has shown that incidence of distant breast\ncancer has been increasing, especially among young women\n(Supplementary Fig",
    "pageHint": 4,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 26,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017813\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 809,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017813\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": null,
    "unit": "year",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017813\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 26,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017813\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 2017813,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017813\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 26,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017813\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 809,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017813\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 2282958,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017813\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 809,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017813\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 1,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017813\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 2026,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "Metastatic Breast Cancer Prevalence\nwww.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017813\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 26,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "www.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017815\nMetastatic Breast Cancer Prevalence\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 809,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "www.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017815\nMetastatic Breast Cancer Prevalence\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1987",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "ByrneJ,Kessler LG,DevesaSS.Theprevalenceofcancer amongadults inthe\nUnited States: 1987",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "1976",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Incidence of Breast Cancer With Distant\nInvolvement Among Women in the United States, 1976 to 2009",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "1976",
    "value": null,
    "unit": "year",
    "population": null,
    "notes": "Incidence of Breast Cancer With Distant\nInvolvement Among Women in the United States, 1976 to 2009",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": null,
    "unit": "year",
    "population": "Metastatic Breast Cancer",
    "notes": "www.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017815\nMetastatic Breast Cancer Prevalence\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "prevalence",
    "yearOrRange": "1987",
    "value": 1987,
    "unit": "cases",
    "population": null,
    "notes": "ByrneJ,Kessler LG,DevesaSS.Theprevalenceofcancer amongadults inthe\nUnited States: 1987",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "1976",
    "value": 1976,
    "unit": "cases",
    "population": null,
    "notes": "Incidence of Breast Cancer With Distant\nInvolvement Among Women in the United States, 1976 to 2009",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Incidence",
    "yearOrRange": "1976",
    "value": 2009,
    "unit": "cases",
    "population": null,
    "notes": "Incidence of Breast Cancer With Distant\nInvolvement Among Women in the United States, 1976 to 2009",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 26,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "www.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017815\nMetastatic Breast Cancer Prevalence\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 2017815,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "www.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017815\nMetastatic Breast Cancer Prevalence\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 26,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "www.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017815\nMetastatic Breast Cancer Prevalence\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 809,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "www.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017815\nMetastatic Breast Cancer Prevalence\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 2282958,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "www.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017815\nMetastatic Breast Cancer Prevalence\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 809,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "www.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017815\nMetastatic Breast Cancer Prevalence\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 1,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "www.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017815\nMetastatic Breast Cancer Prevalence\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-011",
    "filename": "Mariotto_et_al.pdf",
    "metricName": "Prevalence",
    "yearOrRange": "2017",
    "value": 2026,
    "unit": "cases",
    "population": "Metastatic Breast Cancer",
    "notes": "www.aacrjournals.orgCancer Epidemiol Biomarkers Prev; 26(6) June 2017815\nMetastatic Breast Cancer Prevalence\nDownloaded from http://aacrjournals.org/cebp/article-pdf/26/6/809/2282958/809.pdf by guest ",
    "pageHint": 7,
    "needsManualReview": true
  }
]